ACUTE L-DOPA PRETREATMENT POTENTIATES 6-HYDROXYDOPAMINE-INDUCED TOXIC EFFECTS ON NIGRO-STRIATAL DOPAMINE NEURONS IN MICE

被引:18
作者
NAUDIN, B [1 ]
BONNET, JJ [1 ]
COSTENTIN, J [1 ]
机构
[1] FAC MED & PHARM ST ETIENNE, NEUROPSYCHOPHARMACOL EXPTL LAB, CNRS, URA 1969, F-76803 ST ETIENNE, FRANCE
关键词
6-HYDROXYDOPAMINE; L-DOPA THERAPY; PARKINSONS DISEASE; NEUROTOXICITY; DOPAMINE CARRIER (NEURONAL); MICE;
D O I
10.1016/0006-8993(95)00988-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
We have studied the effect of various agents on the decreases in striatal levels of dopamine (DA) and its metabolites which were observed 14 days after an intracerebroventricular (i.c.v.) administration of 50 mu g 6-hydroxydopamine (6-OHDA) to mice. A pretreatment of mice with either a tyrosine hydroxylase inhibitor (alpha-methyl-p-tyrosine), a D-2 receptor agonist (bromocriptine) or antagonist (haloperidol), or a vesicular uptake inhibitor (tetrabenazine) did not modify the 6-OHDA-induced decreases in DA and metabolites, indicating that DA synthesis, vesicular storage and neuronal firing rates are not mainly involved in the 6-OHDA-induced toxicity on the DA neurons. Conversely, a pretreatment with L-DOPA + benserazide potentiated the 6-OHDA-induced decreases in striatal levels of DA, homovanillic acid and 3-methoxy-tyramine, This effect was not due to an increased 6-OHDA uptake via the neuronal carrier since a pretreatment with L-DOPA + benserazide, performed 1-1.5 h before sacrifice, decreased the apparent affinity of the uptake, an effect which disappeared when considering the total DA concentration present in incubation medium ([H-3]DA and cold released DA). In conclusion, potentiation of the 6-OHDA neurotoxicity by L-DOPA rises again the important problem of the safety of the latter drug in therapeutics.
引用
收藏
页码:151 / 157
页数:7
相关论文
共 35 条
[1]  
Ben-Shachar D, 1990, J Neural Transm Suppl, V29, P251
[2]   SIMULTANEOUS EVALUATION BY A DOUBLE LABELING METHOD OF DRUG-INDUCED UPTAKE INHIBITION AND RELEASE OF DOPAMINE IN SYNAPTOSOMAL PREPARATION OF RAT STRIATUM [J].
BONNET, JJ ;
LEMASSON, MH ;
COSTENTIN, J .
BIOCHEMICAL PHARMACOLOGY, 1984, 33 (13) :2129-2135
[3]  
Cohen G, 1983, J Neural Transm Suppl, V19, P89
[4]  
COHEN G, 1974, J BIOL CHEM, V249, P2447
[5]  
FORNSTEDT B, 1990, ACTA NEUROL SCAND, V82, P12
[6]   INVIVO AUTOXIDATION OF DOPAMINE IN GUINEA-PIG STRIATUM INCREASES WITH AGE [J].
FORNSTEDT, B ;
PILEBLAD, E ;
CARLSSON, A .
JOURNAL OF NEUROCHEMISTRY, 1990, 55 (02) :655-659
[7]  
GRAHAM DG, 1978, MOL PHARMACOL, V14, P644
[8]   PHARMACOLOGICAL EFFECTS PRODUCED BY INTRACEREBRAL INJECTION OF DRUGS IN THE CONSCIOUS MOUSE [J].
HALEY, TJ ;
MCCORMICK, WG .
BRITISH JOURNAL OF PHARMACOLOGY AND CHEMOTHERAPY, 1957, 12 (01) :12-15
[9]   PARTIAL LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL SYSTEM IN RAT-BRAIN - BIOCHEMICAL-CHARACTERIZATION [J].
HEFTI, F ;
MELAMED, E ;
WURTMAN, RJ .
BRAIN RESEARCH, 1980, 195 (01) :123-137
[10]   INHIBITION OF BIOGENIC AMINE UPTAKE BY HYDROGEN PEROXIDE - MECHANISM FOR TOXIC EFFECTS OF 6-HYDROXYDOPAMINE [J].
HEIKKILA, R ;
COHEN, G .
SCIENCE, 1971, 172 (3989) :1257-&